Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East
Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East
Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East
RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement
RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement
RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement
Premier, Inc. Honors Program that Helps Low-Income Seniors Age in Place with National Award and $100,000 Donation: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Honors Program that Helps Low-Income Seniors Age in Place with National Award and $100,000 Donation


Aging Gracefully, a nonprofit program dedicated to making homes safer for low-income adults over the age of 65, has received the 2023 Premier Cares Award and a $100,000 cash prize from Premier,

Pfizer Declares Third-Quarter 2023 Dividendhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Declares Third-Quarter 2023 Dividend


Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 third-quarter 2023 dividend on the company’s common stock, payable September 5, 2023, to holders of the Common

Owens & Minor to Participate in UBS Healthcare Services Conference on Tuesday, June 27, 2023: https://mms.businesswire.com/media/20211103005246/en/922805/5/O%26M_LogoTM_hi-res.jpg
Owens & Minor to Participate in UBS Healthcare Services Conference on Tuesday, June 27, 2023


Owens & Minor, Inc. (NYSE: OMI), a global healthcare solutions company that incorporates product manufacturing, distribution support and innovative technology services, announced today that Ed

MD Medical Group Investments Plc: MD Medical Group announces cancellation of listing on LSE
MD Medical Group Investments Plc: MD Medical Group announces cancellation of listing on LSE
MD Medical Group Investments Plc: MD Medical Group announces cancellation of listing on LSE
Cosmo and Hyundai Pharm Announce Signing of License Agreement for Winlevi® in Korea
Cosmo and Hyundai Pharm Announce Signing of License Agreement for Winlevi® in Korea
Cosmo and Hyundai Pharm Announce Signing of License Agreement for Winlevi® in Korea
Simulations Plus Announces Third Quarter Fiscal Year 2023 Earnings and Conference Call Date: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Announces Third Quarter Fiscal Year 2023 Earnings and Conference Call Date


Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report third quarter fiscal 2023 financial results after the market close on Thursday, July 6, 2023.

Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder


Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Dexcom G6 Strengthens Its Position as World’s Most Connected CGM System: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom G6 Strengthens Its Position as World’s Most Connected CGM System


DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Real-Time Continuous Glucose Monitoring System

Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approvalhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval


Pfizer (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved TALZENNA (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with

OSE Immunotherapeutics Receives €1.5 M in Funding from Bpifrance for the Development of a Companion Diagnostic for the Cancer Vaccine Tedopi® in Non-Small Cell Lung Cancer: https://mms.businesswire.com/media/20230215005587/en/545518/5/OSE_LOGO_Horizontal_RVB.jpg
OSE Immunotherapeutics Receives €1.5 M in Funding from Bpifrance for the Development of a Companion Diagnostic for the Cancer Vaccine Tedopi® in Non-Small Cell Lung Cancer


Regulatory News:



OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the Company has received €1.5 million in non-dilutive funding from Bpifrance - Direction

WakeMed Health & Hospitals Wins 2023 Premier Alliance Excellence Award: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
WakeMed Health & Hospitals Wins 2023 Premier Alliance Excellence Award


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, has named WakeMed Health & Hospitals, a nationally recognized 970-bed not-for-profit healthcare system

Pfizer Invites Public to View and Listen to Webcast of August 1 Conference Call with Analystshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to View and Listen to Webcast of August 1 Conference Call with Analysts


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, August 1, 2023. The purpose

Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced three oral presentations at the Annual Meeting of the European Renal Association (ERA), providing additional

Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities


Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the

Almirall launches Nina, the first series to highlight the major impact of psoriasis on patient’s wellbeing: https://mms.businesswire.com/media/20221109006035/en/1631769/5/ALM_AW_LOGO_Tagline_MV_Positive_RGB_%281%29.jpg
Almirall launches Nina, the first series to highlight the major impact of psoriasis on patient’s wellbeing


Psoriasis is a chronic dermatological disease that not only affects the skin but also their mental and social wellbeing. The disease has an impact on all aspects of daily lives and almost 77% of

RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders
Cosmo Pharmaceuticals announces approval of Winlevi® in Canada
Cosmo Pharmaceuticals announces approval of Winlevi® in Canada
Cosmo Pharmaceuticals announces approval of Winlevi® in Canada
Sonova further extends offering of Sennheiser-branded  
hearing solutions with All-Day Clear
Sonova further extends offering of Sennheiser-branded   hearing solutions with All-Day Clear
Sonova further extends offering of Sennheiser-branded   hearing solutions with All-Day Clear
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: Anniversary of BRAIN Biotech AG: 30 years for a bio-based future
EQS-News: Anniversary of BRAIN Biotech AG: 30 years for a bio-based future
EQS-News: Anniversary of BRAIN Biotech AG: 30 years for a bio-based future
Sensorion Reports Promising Preliminary Data from SENS-401 Phase 2a Clinical Study: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Reports Promising Preliminary Data from SENS-401 Phase 2a Clinical Study


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within

Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg
Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today